<DOC>
	<DOCNO>NCT00789711</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study compare clinical safety profile effectiveness NovoMix® 30 Levemir™ treatment diabetes Philippines .</brief_summary>
	<brief_title>An Observational Study Compare Safety Effectiveness NovoMix® 30 Levemir™ Treatment Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Patients diagnose type 1 type 2 diabetes mellitus Patients uncontrolled oral antidiabetic drug Insulin naïve patient patient currently human insulin Subjects unlikely comply protocol requirement Subjects previously enrol NovoMix® 30 Levemir™ study Subjects NovoMix® 30 Levemir™ therapy Subjects hypersensitivity NovoMix® 30 excipients Subjects hypersensitivity Levemir™ excipients Females child bear potential pregnant , breast feed intend become pregnant use adequate contraceptive method ( adequate contraceptive measure require local law practice Contraindications warning specify current prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>